Orhan Aktas Selected Research

Glutaredoxins

1/2022	Glutaredoxin 2 promotes SP-1-dependent CSPG4 transcription and migration of wound healing NG2 glia and glioma cells: Enzymatic Taoism.
1/2017	Iron-sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microglia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Orhan Aktas Research Topics

Disease

61	Multiple Sclerosis 01/2022 - 02/2002
38	Neuromyelitis Optica (Devic's Disease) 01/2022 - 04/2007
21	Optic Neuritis (Retrobulbar Neuritis) 01/2022 - 01/2012
15	Relapsing-Remitting Multiple Sclerosis 01/2021 - 04/2008
14	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 11/2019 - 03/2003
11	Demyelinating Diseases (Demyelinating Disease) 01/2021 - 12/2003
10	Ganglion Cysts (Ganglion) 01/2022 - 01/2012
9	Inflammation (Inflammations) 01/2022 - 03/2003
8	Myelitis 09/2020 - 07/2015
7	Autoimmune Diseases (Autoimmune Disease) 10/2020 - 02/2002
7	Neuroinflammatory Diseases 01/2019 - 12/2003
6	Infections 10/2020 - 08/2005
5	Atrophy 01/2022 - 07/2017
5	Disease Progression 01/2022 - 01/2003
4	Encephalitis (Encephalitis, Rasmussen) 09/2020 - 01/2016
4	Encephalomyelitis (Myeloencephalitis) 09/2020 - 03/2003
4	Susac Syndrome 12/2016 - 01/2012
3	Pain (Aches) 01/2022 - 07/2015
3	Polyneuropathies (Polyneuropathy) 01/2022 - 10/2016
3	Chronic Progressive Multiple Sclerosis 10/2020 - 10/2009
3	Leukocytosis (Pleocytosis) 11/2016 - 01/2012
3	Neoplasms (Cancer) 10/2016 - 05/2007
3	Transverse Myelitis (Necrotizing Myelitis) 01/2016 - 04/2007
2	COVID-19 01/2022 - 01/2021
2	Central Nervous System Diseases (CNS Diseases) 01/2022 - 01/2019
2	Lymphopenia (Lymphocytopenia) 01/2021 - 04/2020
2	Rheumatoid Arthritis 10/2020 - 03/2013
2	Progressive Multifocal Leukoencephalopathy 10/2020 - 08/2019
2	Ischemic Stroke 09/2020 - 01/2019
2	Rubella (German Measles) 09/2020 - 09/2020
2	Herpes Zoster 09/2020 - 09/2020
2	Acute Disseminated Encephalomyelitis (Postinfectious Encephalomyelitis) 09/2020 - 09/2020
2	Measles 09/2020 - 09/2020
2	Stroke (Strokes) 09/2020 - 01/2019
2	Headache (Headaches) 04/2020 - 10/2019
2	Infarction (Infarctions) 01/2020 - 08/2015
2	Paralysis (Palsy) 10/2019 - 03/2003
2	Hypersensitivity (Allergy) 03/2017 - 08/2008
2	Vision Disorders (Hemeralopia) 11/2016 - 09/2015
2	Retinal Artery Occlusion 08/2015 - 06/2013
2	Meningitis 02/2015 - 07/2007
2	Brain Diseases (Brain Disorder) 02/2007 - 11/2004
1	Post-Acute COVID-19 Syndrome 01/2022

Drug/Important Bio-Agent (IBA)

27	Retinaldehyde (Retinal)IBA 01/2022 - 01/2012
17	Immunoglobulin G (IgG)IBA 01/2022 - 05/2007
14	Myelin-Oligodendrocyte GlycoproteinIBA 01/2022 - 01/2011
13	AntibodiesIBA 01/2021 - 04/2007
9	Oligoclonal BandsIBA 01/2022 - 01/2012
7	ocrelizumabIBA 01/2022 - 08/2020
7	Fingolimod Hydrochloride (FTY720)FDA Link 01/2021 - 07/2010
6	Biomarkers (Surrogate Marker)IBA 01/2021 - 08/2015
5	tocilizumab (atlizumab)FDA Link 01/2022 - 03/2013
5	AutoantibodiesIBA 01/2022 - 10/2016
5	Aquaporin 4IBA 01/2021 - 04/2007
5	Monoclonal AntibodiesIBA 01/2021 - 03/2013
5	Natalizumab (Tysabri)FDA Link 01/2021 - 02/2012
5	Proteins (Proteins, Gene)FDA Link 09/2020 - 04/2007
5	LigandsIBA 07/2007 - 02/2002
4	CytokinesIBA 01/2022 - 08/2005
4	inebilizumabIBA 01/2022 - 10/2019
4	Glatiramer Acetate (Copaxone)FDA Link 01/2021 - 01/2003
4	InterferonsIBA 10/2020 - 12/2014
4	Pharmaceutical PreparationsIBA 01/2019 - 01/2012
4	opicinumabIBA 12/2018 - 01/2016
4	AntigensIBA 01/2018 - 04/2007
4	anti-aquaporin 4 autoantibodyIBA 07/2017 - 01/2012
4	Aquaporins (Water Channels)IBA 01/2016 - 02/2012
3	Rituximab (Mabthera)FDA Link 01/2022 - 10/2020
3	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2022 - 03/2013
3	epigallocatechin gallate (epigallocatechin-3-gallate)IBA 01/2021 - 11/2004
3	Interferon-betaIBA 01/2019 - 06/2003
3	Peptides (Polypeptides)IBA 01/2019 - 01/2003
3	IntegrinsIBA 01/2015 - 12/2003
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 04/2008 - 03/2003
3	Atorvastatin (Lipitor)FDA Link 04/2008 - 03/2003
2	GlutaredoxinsIBA 01/2022 - 01/2017
2	Biological ProductsIBA 01/2021 - 10/2020
2	GadoliniumIBA 01/2021 - 05/2019
2	Anti-Bacterial Agents (Antibiotics)IBA 10/2020 - 11/2012
2	Immunosuppressive Agents (Immunosuppressants)IBA 10/2020 - 01/2019
2	Immunoglobulin M (IgM)IBA 09/2020 - 09/2020
2	Immunoglobulin IsotypesIBA 09/2020 - 09/2020
2	Lactic Acid (Lactate)FDA LinkGeneric 09/2020 - 09/2020
2	AlbuminsIBA 09/2020 - 09/2020
2	Immunoglobulin A (IgA)IBA 09/2020 - 09/2020
2	Intravenous Immunoglobulins (IVIG)FDA Link 10/2019 - 01/2003
2	Alemtuzumab (Campath)FDA Link 11/2018 - 01/2015
2	Erythropoietin FDA Link 03/2016 - 01/2016
2	CholesterolIBA 07/2015 - 12/2003
2	MicroRNAs (MicroRNA)IBA 01/2015 - 05/2014
2	CopperIBA 04/2012 - 01/2012
2	Cladribine FDA LinkGeneric 01/2012 - 02/2010
2	NF-kappa B (NF-kB)IBA 08/2008 - 11/2004
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2008 - 05/2005
2	TNF-Related Apoptosis-Inducing LigandIBA 07/2007 - 06/2003
1	dimemorfan (AT 17)IBA 01/2022

Therapy/Procedure

32	Therapeutics 08/2021 - 01/2003
6	Immunotherapy 01/2022 - 01/2017
4	Immunomodulation 01/2022 - 01/2003
2	Plasma Exchange 11/2018 - 11/2016